Clinical Trial Update: A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa [Phase 2]

View source ↗

Summary

Phase 2 pediatric study assessing safety and efficacy of avalglucosidase alfa given every other week in infantile-onset Pompe disease patients previously treate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• NEXVIAZYME (avalglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II-Pompe's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-11-22